Emerging therapeutic targets in non-small cell lung cancer

Proceedings of the American Thoracic Society

Volumn 6, Issue 2, 2009, Pages 218-223

  Dy, Grace K ^a   Adjei, Alex A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Epidermal growth factor receptor; Non small cell lung cancer; Vaccine

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; BEVACIZUMAB; BOSUTINIB; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CIMAVAX EPIDERMAL GROWTH FACTOR; CISPLATIN; CP 751871; CYCLOPHOSPHAMIDE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; LUCANIX; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; RECOMBINANT VACCINE; RECOMBINANT VASCULOTROPIN; SORAFENIB; STIMUVAX; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SAFETY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME; SYSTEMIC THERAPY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOGENESIS INHIBITORS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; LUNG NEOPLASMS; ONCOGENE PROTEIN V-AKT; PROTEIN KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES;

EID: 65349149344     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200808-099LC     Document Type: Conference Paper

References (67)

1. Cerny T, Barnes DM, Hasleton P, Barber PV, Healy K, Gullick W, Thatcher N. Expression of epidermal growth factor receptor (EGF- R) in human lung tumours. Br J Cancer 1986;54:265-269.
2. Lynch TJ, Adjei AA, Bunn PA Jr, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Janne PA, Johnson BE, et al. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agnets. Clin Cancer Res 2006;12:4365s-4371s.
3. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-132.
5. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomized phase III trial. Lancet 2008;372:1809-1818.
6. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-2456.
7. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
9. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
10. Mok T, Wu YL, Thongprasert S, Yang CH, Chu D, Saijo N, Jiang H, Watkins C, Armour A, Fukuoka M. Phase III randomised, open- label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer (IPASS) [abstract]. Ann Oncol 2008;19:viii1.
11. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small- cell lung cancer: a phase III trial. INTACT 1. J Clin Oncol 2004;22: 777-784.
12. Herbst RS, Giaccone G, Schiller J, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial INTACT 2. J Clin Oncol 2004;22:785-794.
13. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
14. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 2005;23:5892-5899.
15. Pirker R, Szczesna A, von Pawel J, et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2008;26:3a.
16. ImClone press release. August 29, 2008. (Accessed 2008 Oct 28) Available from http://www.drugs.com/clinica-trials/erbitux-phase-3-bms-099-lung-cancer- study-secondary-endpoint-update-overall-survival-results-5380.html
17. Folkman J. Antiangiogenic gene therapy. Proc Natl Acad Sci USA 1998; 95:9064-9066.
18. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
19. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62: 5476-5484.
20. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, 3rd, Gaudreault J, Damico LA, et al. Randomized phase II trial comparing bevacizumab plus carbo- platin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
21. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bev- acizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542- 2550.
22. Manegold C, von Pawel J, Zaitloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Reck M. B017704: a phase III randomized study of first-line bevacizumab combined with cisplatin/ gemcitabine (CG) in patients (pts) with advanced or recurrent non- squamous, non-small cell lung cancer (NSCLC) [abstract]. Ann Oncol 2008;19:viii1.
23. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13:1539.
24. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non- small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016-3024.
25. Schiller JH, Lee JW, Hanna NH, Traynor AM, Carbone DP. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501 [abstract]. JClinOncol2008;26: 8014a.
26. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, et al. Multicen- ter, phase II trial of sunitinib in previously treated, advanced non- small cell lung cancer. J Clin Oncol 2008;26:650-656.
27. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer. [Accessed August 25, 2008]. Available from: http://www.medicalnewstoday.com/articles/105387.php
28. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-262.
29. Noro R, Gemma A, Miyanaga A, Kosaihira S, Minegishi Y, Nara M, Kokubo Y, Seike M, Kataoka K, Matsuda K, et al. PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Oncol 2007;31:1157-1163.
30. Minuto F, Del Monte P, Barreca A, Alama A, Cariola G, Giordano G. Evidence for autocrine mitogenic stimulation by somatomedin-C/ insulin-like growth factor I on an established human lung cancer cell line. Cancer Res 1988;48:3716-3719.
31. Kaiser U, Schardt C, Brandscheidt D, Wollmer E, Havemann K. Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer. J Cancer Res Clin Oncol 1993;119: 665-668.
32. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-518.
33. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-430.
34. Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 2008; 11:63-76.
35. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006;66:7864-7869.
36. Hohla F, Schally AV, Szepeshazi K, Varga JL, Buchholz S, Koster F, Heinrich E, Halmos G, Rick FG, Kannadka C, et al. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc Natl Acad Sci USA 2006;103:14513-14518.
37. Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone- releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008;4:33-43.
38. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Gualberto A, Langer CJ. High activity of the anti-IGF-1R antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC [abstract]. JClin Oncol 2008;26: 8015a.
39. Molina JR, Mandrekar SJ, Rowland KR, Reuter NF, Jett JR, Marks R, Schild SE, Adjei A. A phase II NCCTG ''Window of Opportunity Front-line'' study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC [abstract]. J Thorac Oncol 2007;2:S413.
40. Papadimitrakopoulou V, Soria JC, Douillard JY, Giaccone G, Wolf J, Crino L, Cappuzzo F, Sharma S, Gross SH, Shepherd FA. A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum- based chemotherapy (C) or prior C and EGFR inhibitors [abstract]. J Clin Oncol 2007;25:406s.
41. Zeng L, Si X, Yu WP, et al. PTP alpha regulates integrin-stimulated FAK autophosphorylation and cytoskeletal rearrangement in cell spreading and migration. J Cell Biol 2003;160:137-146.
42. Boyer B, Valles Am, Edme N. Induction and regulation of epithelialmesenchymal transitions. Biochem Pharmacol 2000;60:1091-1099.
43. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, et al. Restoring E- cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66:944- 950.
44. Mazurenko NN, Kogan EA, Zborovskaya IB, Kisseljov FL. Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 1992;28:372-377.
45. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angio- genesis and vascular permeability. Mol Cell 1999;4:915-924.
46. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-4165.
47. Laird AD, Li G, Moss KG, Blake RA, Broome MA, Cherrington JM, Mendel DB. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphor- ylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumour cells. Mol Cancer Ther 2003;2:461-469.
48. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66:5542-5548.
49. Messersmith WA, Krishnamurthi S, Hewes BA, Zacharchuk CM, Abbas R, Martins P, Dowling E, Volkert A, Martin E, Daud AI. Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: preliminary results from a phase 1 study in patients with advanced malignant solid tumours [abstract]. J Clin Oncol 2007;25:3553a.
50. Boccacio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-645.
51. Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer (In press).
52. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043.
53. Fujita Y, Krause G, Scheffner M, Zechner D, Leddy HE, Behrens J, Sommer T, Birchmeier W. Hakai, a Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002;4:222-231.
54. Pece S, Gutkind S. E-cadherin and Hakai: signaling, remodeling or destruction? Nat Cell Biol 2002;4:E72-E74.
55. Coley WB. Contribution to the knowledge of sarcoma. Ann Surg 1891; 14:199-220.
56. Nemunaitis JJ. Are vaccines making a comeback in non-small cell lung cancer? J Clin Oncol 2008;26:1402-1403.
57. Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 2008;29:109-126.
58. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Gnjatic S. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 2008;105:1650-1655.
59. Karsten U, von Mensdorff-Pouilly S, Goletz S. What makes MUC1 a tumor antigen? Tumour Biol 2005;26:217-220.
60. Butts CM, Maksymiuk A, Goss G, Soulieres D, Marshall E, Cormier Y, Ellis PM, Price A, Sawhney R, Murray NA. A multicentre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B1-01 [abstract]. J Thorac Oncol 2007;2:S332-S333.
61. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-625.
62. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11:8055-8062.
63. Vansteenkiste J, Zielinski M, Linder A, Dahabre J, Esteban E, Malinowski W, Jassem J, Passlick B, Lehmann F, Brichard V. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). [abstract]. J Clin Oncol 2007;25:398S.
64. Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M, Stamatis G, Passlick B. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg 2004;25:131-134.
65. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small- cell lung cancer. J Clin Oncol 2006;24:4721-4730.
66. Neninger Vinageras EN, de la Torre A, Osorio Rodriguez M, Catala Ferrer M, Bravo I, Mendoza del Pino M, Abreu Abreu D, Acosta Brooks S, Rives R, del Castillo Carrillo C, et al. Phase II randomized controlled trial of epidermal growth factor vaccine in advanced non- small-cell lung cancer. J Clin Oncol 2008;26:1452-1458.
67. Van Cutsem, Lang I, D'Haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Nippgen J, Stroh C, Rougier P. Kras status and efficacy in the CRYSTAL study: 1st-line treatment of patients with metastatic colorectal cancer (MCRC) receiving FOLFIRI with or without cetuximab [abstract]. Ann Oncol 2008;19(S8):viii44-viii45.